EDEN PRAIRIE, Minn., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today its financial results for the third quarter ended September 30, 2016. The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s recently announced strategic realignment, including the acquisition of the Aquadex FlexFlow® business.
To access the live webcast, please visit the Investors page of the Sunshine Heart website at ir.sunshineheart.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 4610509. An audio archive of the webcast and a transcript of the call will be available following the call at ir.sunshineheart.com.
- As part of strategic realignment, the Company continues to execute near-term strategy to drive growth with the recently acquired Aquadex FlexFlow business.
- Direct field organization providing service to the top 50 hospital accounts that have purchased Aquadex over the past 12 months.
- Pursuing post-market clinical data collection to strengthen evidence for using Aquadex in an outpatient setting.
- In July, completed a registered direct offering of convertible preferred shares and a private placement of stock warrants for total gross proceeds of approximately $3.5 million. In August, the company repaid all outstanding borrowings to Silicon Valley Bank of $6.0 million and completed the Aquadex acquisition for $4.0 million in cash and 1 million shares of common stock.
- In October, completed a registered direct offering and a private placement of convertible preferred shares and stock warrants for total gross proceeds of approximately $3.6 million.
- Reduced operating expenses in Q3, down over 30% from a year ago; Q4 operating expenses expected to decrease over 50% from a year ago.
- NASDAQ hearing scheduled for mid-November to petition for a further extension of time in order to meet listing requirements.
“It was a challenging quarter and a difficult decision to put our neuromodulation strategy on pause due solely to financial constraints,” said John Erb, Chairman and CEO. “While we continue to believe in the long term potential of the neuromodulation opportunity, focusing all of our efforts on growing our Aquadex business will be critical to bolstering our financial strength and will allow Sunshine Heart to strengthen its presence in the heart failure market.”
|SUNSHINE HEART, INC. AND SUBSIDIARIES|
|Condensed Consolidated Statements of Operations and Comprehensive Loss|
|(In thousands, except per share amounts)|
|Three months ended |
|Nine months ended|
|Costs and Expenses:|
|Cost of goods sold||187||—||187||—|
|Selling, general and administrative||2,683||1,725||5,444||6,259|
|Research and development||1,735||4,548||7,511||13,404|
|Total costs and expenses||4,605||6,273||13,142||19,663|
|Loss from operations||(4,062||)||(6,273||)||(12,599||)||(19,604||)|
|Other income (expense):|
|Loss on early retirement of long-term debt||(500||)||—||(500||)||—|
|Other income (expense), net||2||(2||)||2||(1||)|
|Change in fair value of warrant liability||646||—||646||—|
|Total other income (expense)||80||(282||)||(356||)||(499||)|
|Loss before income taxes||(3,982||)||(6,555||)||(12,955||)||(20,103||)|
|Income tax benefit (expense), net||65||(3||)||64||124|
|Basic and diluted loss per share||$||(0.27||)||$||(0.36||)||$||(0.76||)||$||(1.11||)|
|Weighted average shares outstanding – basic and diluted||19,974||18,330||18,910||18,045|
|Other comprehensive income:|
|Foreign currency translation adjustments||$||(6||)||$||(16||)||$||(12||)||$||(22||)|
|Total comprehensive loss||$||(3,923||)||$||(6,574||)||$||(12,903||)||$||(20,001||)|
|SUNSHINE HEART, INC. AND SUBSIDIARIES|
|Condensed Consolidated Balance Sheets|
|(In thousands, except share and per share amounts)|
|September 30, |
|December 31, |
|Cash and cash equivalents||$||792||$||23,113|
|Other current assets||223||479|
|Total current assets||1,328||23,592|
|Property, plant and equipment, net||597||535|
|Intangible assets, net||4,399||—|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Current portion of long-term debt||$||—||$||3,798|
|Accounts payable and accrued expenses||2,169||2,832|
|Total current liabilities||2,798||7,998|
|Long-term debt, net of discount and financing fees||—||3,881|
|Common stock warrant liability||1,237||—|
|Commitments and contingencies||—||—|
|Series A junior participating preferred stock as of September 30, 2016 and December 31, 2015, par value $0.0001 per share; authorized 30,000 shares, none outstanding||—||—|
|Series B convertible preferred stock as of September 30, 2016 and December 31, 2015, par value $0.0001 per share; authorized 3,468 shares, issued and outstanding 2,227 and 0, respectively||—||—|
|Preferred stock as of September 30, 2016 and December 31, 2015, par value|
$0.0001 per share; authorized 39,966,532 shares, none outstanding
|Common stock as of September 30, 2016 and December 31, 2015, par value|
$0.0001 per share; authorized 100,000,000 shares, issued and outstanding
20,866,217 and 18,344,478, respectively
|Additional paid‑in capital||167,297||164,105|
|Accumulated other comprehensive income:|
|Foreign currency translation adjustment||1,234||1,246|
|Total stockholders’ equity||2,460||12,171|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||6,621||$||24,450|
|SUNSHINE HEART, INC. AND SUBSIDIARIES|
|Condensed Consolidated Statements of Cash Flows|
|Nine months ended|
|Adjustments to reconcile net loss to cash flows used in operating activities:|
|Depreciation and amortization expense||457||241|
|Stock-based compensation expense, net||764||1,811|
|Amortization of debt discount and financing fees||187||102|
|Loss on early retirement of long-term debt||500|
|Change in fair value of warrant liability||(646||)||—|
|Changes in operating assets and liabilities:|
|Other current assets||256||(406||)|
|Other assets and liabilities||(471||)||(108||)|
|Accounts payable and accrued expenses||(1,406||)||48|
|Net cash used in operations||(13,563||)||(18,232||)|
|Purchases of property and equipment||(110||)||(175||)|
|Acquisition of Aquadex product line||(4,000||)||—|
|Net cash used in investing activities||(4,110||)||(175||)|
|Net proceeds from the sale of preferred stock and common stock||3,362||7,055|
|Proceeds from (repayments on) borrowings on long-term debt||(8,000||)||8,000|
|Net cash (used in) provided by financing activities||(4,638||)||15,055|
|Effect of exchange rate changes on cash||(10||)||(42||)|
|Net decrease in cash and cash equivalents||(22,321||)||(3,394||)|
|Cash and cash equivalents - beginning of period||23,113||31,293|
|Cash and cash equivalents - end of period||$||792||$||27,899|
|Supplement schedule of non-cash activities|
|Warrants issued in connection with debt financing||$||—||$||355|
|Common stock issued for business acquisition||$||950||$||—|
|Supplemental cash flow information|
|Cash paid for interest||$||840||$||247|
|Cash paid for income taxes||$||47||$||—|
About Sunshine Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing a product portfolio to treat moderate to severe heart failure and related conditions. The Company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Our objective is to improve the quality of life for heart failure patients and slow the disease progression. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.
Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our ability to execute on our recently announced strategic realignment, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses. The risk factors described in our filings with the SEC could cause actual events to adversely differ from the expectations indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sunshine Heart does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Sunshine Heart may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our therapy, the possibility we may be unable to raise the funds necessary for the development and commercialization of our therapy and other risks and uncertainties described in our filings with the SEC. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact: Claudia Napal Drayton Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4205 Investor Relations Sunshine Heart Inc. firstname.lastname@example.org
Source:Sunshine Heart, Inc.